HUTCHMED (China) Ltd
sovleplenib
warm antibody autoimmune hemolytic anemia
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews sovleplenib for warm antibody autoimmune hemolytic anemia around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 11h ago
“The Phase III results will be presented at the upcoming European Hematology Association (EHA) Congress 2026.”